Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

teva b.v. - bortezomib - prašek za raztopino za injiciranje - bortezomib 3,5 mg / 1 viala - bortezomib

Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

hospira uk ltd. - remifentanil - prašek za koncentrat za raztopino za injiciranje/infundiranje - remifentanil 2 mg / 1 viala - remifentanil

Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

hospira uk ltd. - remifentanil - prašek za koncentrat za raztopino za injiciranje/infundiranje - remifentanil 5 mg / 1 viala - remifentanil

Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

csl behring gmbh - inhibitor c1-esteraze - prašek in vehikel za raztopino za injiciranje/infundiranje - inhibitor c1-esteraze 500 i.e. / 1 viala - zaviralec c1, pridobljen iz plazme

Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fresenius kabi deutschland gmbh - ropivakainijev klorid - raztopina za injiciranje - ropivakainijev klorid 10 mg / 1 ml - ropivakain

Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fresenius kabi deutschland gmbh - ropivakainijev klorid - raztopina za injiciranje - ropivakainijev klorid 7,5 mg / 1 ml - ropivakain

Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fresenius kabi deutschland gmbh - remifentanil - prašek za koncentrat za raztopino za injiciranje/infundiranje - remifentanil 1 mg / 1 viala - remifentanil

Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - meropenem - prašek za raztopino za injiciranje/infundiranje - meropenem 1000 mg / 1 viala - meropenem

Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - meropenem - prašek za raztopino za injiciranje/infundiranje - meropenem 500 mg / 1 viala - meropenem

Ευρωπαϊκή Ένωση - Σλοβενικά - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cepiva - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. uporaba tega cepiva mora biti v skladu z uradnimi priporočili.